Review
doi: 10.1159/000205876.
Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies
Affiliations
- PMID: 3120473
- DOI: 10.1159/000205876
Item in Clipboard
Review
Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies
Acta Haematol.
1987.
Abstract
This paper reviews the factors governing the rate of iron loading and iron toxicity in the thalassaemia syndromes and sickle cell disease. It outlines the main determinants of iron mobilization by the iron-chelating drug, desferrioxamine, together with the effects of this drug in clinical practice.
Similar articles
-
Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.Am J Hematol. 2008 Apr;83(4):263-70. doi: 10.1002/ajh.21049. Am J Hematol. 2008. PMID: 17924547
-
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x. Br J Haematol. 2007. PMID: 17233848 Free PMC article. Clinical Trial.
-
The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.Helv Paediatr Acta. 1966 Sep;21(4):343-50. Helv Paediatr Acta. 1966. PMID: 5997620 No abstract available.
-
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 26893541 Free PMC article. Review.
-
Clinical Management of Patients With Thalassemia Syndromes.Clin J Oncol Nurs. 2016 Jun 1;20(3):310-7. doi: 10.1188/16.CJON.310-317. Clin J Oncol Nurs. 2016. PMID: 27206298 Review.
Cited by
-
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.ScientificWorldJournal. 2012;2012:949535. doi: 10.1100/2012/949535. Epub 2012 Aug 1. ScientificWorldJournal. 2012. PMID: 22924029 Free PMC article. Review.
-
Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major.J Magn Reson Imaging. 2009 Feb;29(2):357-64. doi: 10.1002/jmri.21666. J Magn Reson Imaging. 2009. PMID: 19161188 Free PMC article.
-
Optimal management strategies for chronic iron overload.Drugs. 2007;67(5):685-700. doi: 10.2165/00003495-200767050-00004. Drugs. 2007. PMID: 17385941 Review.
-
Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.J Med Chem. 2012 Aug 23;55(16):7090-103. doi: 10.1021/jm300509y. Epub 2012 Aug 13. J Med Chem. 2012. PMID: 22889170 Free PMC article.
-
Logarithmic quantitation model using serum ferritin to estimate iron overload in secondary haemochromatosis.Arch Dis Child. 1996 Apr;74(4):323-7. doi: 10.1136/adc.74.4.323. Arch Dis Child. 1996. PMID: 8669933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
